Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that is spreading rapidly, which seriously impacts global public health and economy. Thus, developing effective drugs remains urgent. We identify two potent antibodies, nCoVmab1 and nCoVmab2, targeting the SARS-CoV-2 spike protein receptor-binding domain (RBD) with high affinities from a naïve human phage-displayed Fab library. nCoVmab1 and nCoVmab2 neutralize authentic SARS-CoV-2 with picomolar and nanomolar IC 50 values, respectively. No detectable defects of nCoVmab1 and nCoVmab2 are found during the preliminary druggability evaluation. nCoVmab1 could reduce viral titer and lung injury when administered prophylactically and therapeutically in human angiotensin-converting enzyme II (hACE2)-transgenic mice. Therefore, phage display platform could be efficiently used for rapid development of neutralizing monoclonal antibodies (nmabs) with clinical potential against emerging infectious diseases. In addition, we determinate epitopes in RBD of these antibodies to elucidate the neutralizing mechanism. We also convert nCoVmab1 and nCoVmab2 to their germline formats for further analysis, which reveals the contribution of somatic hypermutation (SHM) during nCoVmab1 and nCoVmab2 maturation. Our findings not only provide two highly potent nmabs against SARS-CoV-2 as prophylactic and therapeutic candidates, but also give some clues for development of anti-SARS-CoV-2 agents (e.g., drugs and vaccines) targeting the RBD. Applying neutralizing antibodies against SARS-CoV-2 to infected patients is a promising anti-viral treatment strategy. Here, Zhao et al. derive RBD-targeting monoclonal antibodies from a naïve human phage-displayed Fab library and show their prophylactic and therapeutic potential in hACE2-transgenic mice.
【저자키워드】 SARS-CoV-2, viral infection, 【초록키워드】 severe acute respiratory syndrome coronavirus 2, neutralizing antibody, antibodies, coronavirus, Infectious diseases, Diseases, Vaccines, Neutralizing antibodies, antibody, monoclonal antibody, Emerging infectious diseases, Economy, drug, Lung injury, Prophylactic, severe acute respiratory syndrome Coronavirus, monoclonal antibodies, anti-SARS-CoV-2, Spike protein, hACE2, Novel coronavirus, effective drugs, Epitopes, Viral, mice, RBD, Impact, therapeutic, Neutralizing, respiratory, epitope, platform, mechanism, neutralizing monoclonal antibodies, neutralizing monoclonal antibody, Fab, Analysis, angiotensin, Candidates, acute respiratory syndrome, Anti-viral treatment, acute respiratory syndrome coronavirus, infected patients, maturation, global public health, domain, human Angiotensin-converting enzyme, high affinity, naïve, germline, viral titer, Administered, neutralize, identify, addition, detectable, infected patient, the RBD, reduce, reveal, Applying, determinate, effective drug, prophylactically, the SARS-CoV-2, 【제목키워드】 neutralizing antibody, identification, implication,